Sickle cell disease (SCD) is the most common hemoglobinopathy, characterized by hemolysis and vaso-occlusion, resulting in multisystem disease. Pregnant patients with SCD may have preexisting organ dysfunction and SCD-specific pregnancy complications. Risk for adverse maternal or fetal outcomes is significantly elevated in SCD patients, and multidisciplinary care in a center with expertise is essential to minimize complications.
MalinowskiAKKuoKHMTomlinsonG A, et al. Distinct maternal and fetal pregnancy outcomes in women with sickle cell disease can be predicted using routine clinical and laboratory data. Br J Haematol2021; 194: 1063–1073.
3.
Oteng-NtimEAyensah BKnightM, et al. Pregnancy outcome in patients with sickle cell disease in the UK-a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. Br J Haematol2015; 169: 129–137.
4.
GladwinMTVichinskyE. Pulmonary complications of sickle cell disease. N Engl J Med2008; 359: 2254–2265.
5.
GardnerKDouiriADrasarE, et al.Survival in adults with sickle cell disease in a high-income setting. Blood2016; 128: 1436–1438.
6.
DimitriadisERolnikDLZhouW, et al.Pre-eclampsia. Nat Rev Dis Primers2023; 9: 8.
7.
ZurRLKingdomJCParksWT, et al.The placental basis of fetal growth restriction. Obstet Gynecol Clin North Am2020; 47: 81–98.
8.
Sánchez-ArangurenLCPradaCERiaño-MedinaCE, et al.Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol2014; 5: 372.
9.
MalinowskiAKDziegielewskiCKeatingS, et al.Placental histopathology in sickle cell disease: a descriptive and hypothesis-generating study. Placenta2020; 95: 9–17.
10.
CordierAGBouvierASVibertF, et al.Preserved efficiency of sickle cell disease placentas despite altered morphology and function. Placenta2020; 100: 81–88.
11.
Oteng-NtimEPavordSHowardR, et al.Management of sickle cell disease in pregnancy. A British society for haematology guideline. Br J Haematol2021; 194: 980–995.
12.
VrettouCKakourouGMamasT, et al.Prenatal and preimplantation diagnosis of hemoglobinopathies. Int J Lab Hematol2018; 40: 74–82.
13.
Canadian, Association. H. Contraception, Pre-Conception Counseling, and Pregnancy. In: Consensus Statement on the Care of Patients with Sickle Cell Disease in Canada. Ottowa. 2015; 88–91.
14.
JainDAtmapoojyaPColahR, et al.Sickle cell disease and pregnancy. Mediterr J Hematol Infect Dis2019; 11: e2019040.
15.
YasinFMcGannPVan DorenL. Hydroxyurea in pregnancy: Reframing the conversation. Am J Hematol2024; 99: 1214–1216.
SinkeyRGOgunsileFJKanterJ, Medicine SfM-F, et al. Society for maternal-fetal medicine consult series #68: sickle cell disease in pregnancy. Am J Obstet Gynecol. 2024;230:B17–B40.
18.
JamesAHStrouseJJ. How I treat sickle cell disease in pregnancy. Blood2024; 143: 769–776.
19.
SharmaDKozanoğluIAtagaKI, et al.Managing sickle cell disease and related complications in pregnancy: results of an international delphi panel. Blood Adv2024; 8: 1018–1029.
20.
BrousseVBuffetPReesD. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol2014; 166: 165–176.
21.
RubinLGLevinMJLjungmanP, et al.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–318.
22.
LiemRILanzkronSD CoatesT, et al.American Society of hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv2019; 3: 3867–3897.
23.
JosephLDriessenM. A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality. Lancet Haematol2024; 11: e75–e84.
24.
Regitz-ZagrosekVRoos-HesselinkJWBauersachsJ, et al.2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39:3165–3241.
25.
AsareEVDeBaunMROlayemiE, et al.Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy. Hematology Am Soc Hematol Educ Program. 2022; 2022: 388–407.
26.
ChangJNMagannEFNovotnySA, et al.Maternal/perinatal outcome in women with sickle cell disease: a comparison of two time periods. South Med J2018; 111: 742–745.
27.
Martí-CarvajalAJPeña-MartíGEComunián-CarrascoG, et al.Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database Syst Rev2009; 2009: CD006786.
28.
National Institute for Health and Clinical Excellence (NICE Guideline). Sickle cell disease: managing acute painful episodes in hospital. Clinical guideline CG143. Internet2012. Available: https://www.nice.org.uk/guidance/CG143. Accessed 24 October 2025.
29.
ShirelTHublerCPShahR, et al.Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease. Am J Hematol2016; 91: 416–419.
30.
NnoliASeligmanNSDysartK, et al.Opioid utilization by pregnant women with sickle cell disease and the risk of neonatal abstinence syndrome. J Natl Med Assoc2018; 110: 163–168.
31.
Committee Opinion No. 711 Summary: opioid use and opioid use disorder in pregnancy. Obstet Gynecol2017; 130: 488–489.
32.
VichinskyEPNeumayrLDEarlesAN, et al.Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med2000; 342: 1855–1865.
33.
HowardJHartNRoberts-HarewoodM, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol2015; 169: 492–505.
34.
KavanaghPLFasipeTAWunT. Sickle cell disease: a review. JAMA2022; 328: 57–68.
35.
MalinowskiAKParrishJD'SouzaR, et al.Adverse outcome of acute splenic sequestration crisis in pregnancy. Obstet Med. 2021; 14: 113–115.
36.
de MontalembertMVoskaridouEOevermannL, et al.Real-Life experience with hydroxyurea in patients with sickle cell disease: results from the prospective ESCORT-HU cohort study. Am J Hematol2021; 96: 1223–1231.
37.
XuJZimmerDB. Differential regulation of A gamma and G gamma fetal hemoglobin mRNA levels by hydroxyurea and butyrate. Exp Hematol1998; 26: 265–272.
38.
Al SulaimaniRZitounNAlothmanH, et al.Safety of hydroxyurea in pregnancy: a systematic review of the literature. J Obstet Gynaecol Can2025; 47: 102924.
39.
DongMWareREDallmannA, et al. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: current evidence and knowledge gaps. Pharmacotherapy2023; 43: 419–429.
40.
HabibiACannasGBartolucciP, et al.Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study. Biomedicines2023; 11: 597.
41.
WareREMarahattaAWareJL, et al.Hydroxyurea exposure in lactation: a pharmacokinetics study (HELPS). J Pediatr2020; 222: 236–239.
42.
DavisBAAllardSQureshiA, et al.Guidelines on red cell transfusion in sickle cell disease part II: indications for transfusion. Br J Haematol2017; 176: 192–209.
43.
ChouSTAlsawasMFasanoRM, et al.American Society of hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv2020; 4: 327–355.
44.
MalinowskiAKParrishJShehataN, et al.Approach to transfusion in pregnant women with sickle cell disease: a survey of physicians. Br J Haematol2018; 183: 516–519.
45.
MalinowskiAKShehataNSouzaD, et al.Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood2015; 126: 2424–2435. quiz 37.
46.
OakleyLLAwogbadeMBrienS, et al.Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial. Trials2020; 21: 347.
47.
HabibiABenachiALecarpentierE.Managing pregnancy in patients with sickle cell disease from a transfusion perspective. Hematology Am Soc Hematol Educ Program2023; 2023: 640–645.
48.
SinsJWBiemondBJvan den BersselaarSM, et al.Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Am J Hematol2016; 91: 763–769.
49.
RosseWFGallagherDKinneyTR, et al.Transfusion and alloimmunization in sickle cell disease. The cooperative study of sickle cell disease. Blood1990; 76: 1431–1437.
50.
Balbuena-MerleRHendricksonJE. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Transfus Clin Biol2019; 26: 112–115.
51.
Mekontso DessapAPirenneFRazaziK, et al.A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol2016; 91: 1181–1184.
52.
HabibiAMekontso-DessapAGuillaudC, et al.Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol2016; 91: 989–994.
53.
DumasGHabibiAOnimusT, et al.Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood2016; 127: 1062–1064.
54.
NarbeyDHabibiAChadebechP, et al.Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol2017; 92: 1340–1348.
55.
EarlyMLRajaMLuoA, et al.Blood pressure thresholds for the diagnosis of hypertensive disorders of pregnancy in sickle cell disease. Br J Haematol2024; 204: 1039–1046.
56.
RolnikDLWrightDPoonLC, et al.Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med2017; 377: 613–622.
57.
SinkeyRGBattarbeeANBelloNA, et al.Prevention, diagnosis, and management of hypertensive disorders of pregnancy: a comparison of international guidelines. Curr Hypertens Rep2020; 22: 66.
58.
GomesFAshornPAskariS, et al.Calcium supplementation for the prevention of hypertensive disorders of pregnancy: current evidence and programmatic considerations. Ann N Y Acad Sci2022; 1510: 52–67.
59.
McGoldrickEStewartFParkerR, et al.Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev2020; 12: CD004454.
60.
WangFMandelbrotLAffoL, et al.Impact of prenatal corticosteroid therapy on sickle cell disease in pregnant women. Int J Gynaecol Obstet2023; 163: 243–255.
61.
ElengaNAdelineABalcaenJ, et al.Pregnancy in sickle cell disease is a very high-risk situation: an observational study. Obstet Gynecol Int. 2016;2016:9069054.
62.
CoatesTDWoodJC. How we manage iron overload in sickle cell patients. Br J Haematol2017; 177: 703–716.
63.
TavaresAHJBenitesBDFertrinKY. Myocardial iron overload in sickle cell disease: a rare but potentially fatal complication of transfusion. Transfus Med Rev2019; 33: 170–175.
64.
MacciòAMadedduCChessaP, et al.Use of erythropoiesis stimulating agents for the treatment of anaemia and related fatigue in a pregnant woman with HbH disease. Br J Haematol2009; 146: 335–337.
65.
DiamantidisMDNeokleousNAgapidouA, et al.Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?Int J Hematol2016; 103: 537–544.
66.
OgbennaAAAkinseteAMKalejaiyeOO, et al.Reduction in seroprevalence of viral transfusion-transmitted infections in southwest Nigeria in children with sickle cell disease using an enhanced screening strategy. Br J Haematol2022; 198: 745–752.
67.
BarnesLSStanleyJBlochEM, et al.Status of hospital-based blood transfusion services in low-income and middle-income countries: a cross-sectional international survey. BMJ Open2022; 12: e055017.
68.
ChangJYJangHChungBH, et al.The successful clinical outcomes of pregnant women with advanced chronic kidney disease. Kidney Res Clin Pract2016; 35: 84–89.
69.
SienasLWongTCollinsR, et al.Contemporary uses of erythropoietin in pregnancy: a literature review. Obstet Gynecol Surv2013; 68: 594–602.
70.
HanJZhouJKondraguntaV, et al.Erythropoiesis-stimulating agents in sickle cell anaemia. Br J Haematol2018; 182: 602–605.
GordeukVRCastroOLMachadoRF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood2016; 127: 820–828.
73.
MalinowskiAKShehataN. Sickle chest syndromes in pregnancy. In: LapinskySEPlanteLA (eds) Respiratory disease in pregnancy. Cambridge: Cambridge University Press, 2020, pp.113–125.
74.
FitzgeraldMFaganKHerbertDE, et al. ., Jr Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using Doppler echocardiography. South Med J. 2012;105:300–305.
75.
Cramer-BourCRuhlAPNouraieSM, et al.Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease. Eur J Haematol2021; 107: 54–62.
76.
SheikhABNasrullahALopezED, et al.Sickle cell disease-induced pulmonary hypertension: a review of pathophysiology, management, and current literature. Pulse (Basel). 2021;9:57–63.
77.
ObadinaMAChangAOwensI, et al.Maternal sleep-associated hypoxemia is common during pregnancy in sickle cell disease: a retrospective review. Am J Obstet Gynecol MFM2025; 7: 101676.
78.
AtagaKISarafSLDerebailVK. The nephropathy of sickle cell trait and sickle cell disease. Nat Rev Nephrol2022; 18: 361–377.
79.
GaudjiGRBidaMConradieM, et al.Renal Papillary Necrosis (RPN) in an African Population: Disease Patterns, Relevant Pathways, and Management. Biomedicines2022; 11: 93.
80.
MilnerPFKrausAPSebesJI, et al.Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med1991; 325: 1476–1481.
81.
PoignardAFlouzat-LachanietteCHAmzallagJ, et al.The natural progression of symptomatic humeral head osteonecrosis in adults with sickle cell disease. J Bone Joint Surg Am2012; 94: 156–162.
82.
GiordanoPUrbanoFLassandroG, et al.Mechanisms of Bone Impairment in Sickle Bone Disease. Int J Environ Res Public Health2021; 18: 1832.
83.
Al-TurkiH. Influence of pregnancy on bone mass in sickle cell anemia. West Afr J Med2009; 28: 169–172.
84.
GhodsSPourEKFaghihiH, et al.Sickle cell trait presenting as unilateral proliferative retinopathy and macular thinning in a pregnant woman. Case Rep Ophthalmol Med2021; 2021: 5988889.
85.
GardnerKSuddleAKaneP, et al.How we treat sickle hepatopathy and liver transplantation in adults. Blood2014; 123: 2302–2307.
86.
HobsonSRCohenERGandhiS, et al.Guideline No. 452: diagnosis and management of intrahepatic cholestasis of pregnancy. J Obstet Gynaecol Can2024; 46: 102618.
87.
KirkhamFJLagunjuIA. Epidemiology of Stroke in Sickle Cell Disease. J Clin Med2021; 10: 4232.
88.
KarjalainenLTikkanenMRantanenK, et al.Pregnancy-associated stroke -a systematic review of subsequent pregnancies and maternal health. BMC Pregnancy Childbirth2019; 19: 187.
89.
ScottRMSmithER. Moyamoya disease and moyamoya syndrome. N Engl J Med2009; 360: 1226–1237.
90.
BoothCInusaBObaroSK. Infection in sickle cell disease: a review. Int J Infect Dis2010; 14: e2–e12.
91.
TamouzaRNeonatoMGBussonM, et al.Infectious complications in sickle cell disease are influenced by HLA class II alleles. Hum Immunol2002; 63: 194–199.
92.
JamesAHJamisonMGBrancazioLR, et al.Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol2006; 194: 1311–1315.
93.
AgarwalSStanekJRVeselySK, et al.Pregnancy-related thromboembolism in women with sickle cell disease: an analysis of national medicaid data. Am J Hematol2023; 98: 1677–1684.
94.
Mapombo ChoupaSBLuoAZarkaC, et al.Risk factors for thrombosis in pregnant people with sickle cell disease: a multinational study. Blood2023; 142: 807.
95.
VillersMSJamisonMGCastroD, et al.Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol2008; 199: 125.e1–5
96.
YuCKStasiowskaEStephensA, et al.Outcome of pregnancy in sickle cell disease patients attending a combined obstetric and haematology clinic. J Obstet Gynaecol2009; 29: 512–516.
97.
BouletSLOkorohEMAzonobiI, et al.Sickle cell disease in pregnancy: maternal complications in a medicaid-enrolled population. Matern Child Health J2013; 17: 200–207.
98.
Oteng-NtimEMeeksDSeedPT, et al.Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood2015; 125: 3316–3325.
99.
WrightEAudetteMCYeXY, et al.Maternal vascular malperfusion and adverse perinatal outcomes in low-risk nulliparous women. Obstet Gynecol2017; 130: 1112–1120.
100.
KingdomJAshwalELausmanA, et al.Guideline No. 442: fetal growth restriction: screening, diagnosis, and management in singleton pregnancies. J Obstet Gynaecol Can2023; 45: 102154.
101.
BrownMAMageeLAKennyLC, et al.The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens2018; 13: 291–310.
102.
EarlyMLLuoASolowM, et al.Natural history of blood pressure in sickle cell disease pregnancy. Br J Haematol2024; 204: 658–667.
103.
CamousJN'daAEtienne-JulanM, et al.Anesthetic management of pregnant women with sickle cell disease–effect on postnatal sickling complications. Can J Anaesth. 2008;55:276–283.
104.
LohJMalinowskiKAWardR, et al.Risk factors for postnatal complications in people with sickle cell disease: a preliminary analysis. Blood2023; 142: 3904. 2023.
105.
ZipurskyJSGomesTEverettK, et al.Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study. Br Med J2023; 380: e074005.
106.
MadadiPRossCJHaydenMR, et al.Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther2009; 85: 31–35.
107.
QureshiAIMalikAAAdilMM, et al.Oral contraceptive use and incident stroke in women with sickle cell disease. Thromb Res2015; 136: 315–318.
108.
BalaNSStanekJRVeselySK, et al.Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception. Blood Adv2023; 7: 6140–6150.
109.
De SanctisVSolimanATDaarS, et al.Current issues and options for hormonal contraception in adolescents and young adult women with sickle cell disease: an update for health care professionals. Mediterr J Hematol Infect Dis. 2020; 12: e2020032.
110.
CurtisKMTepperNKJatlaouiTC, et al.U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep2016; 65: 1–103.
